ClinicalTrials.Veeva

Menu
H

Hospital Regional Universitario de Malaga | Hospital Civil - Rheumatology Department

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Magrolimab
Pembrolizumab
Azacitidine
Amrubicin
Topotecan
Tiragolumab
Venetoclax
Bemarituzumab
Lurbinectedin
Atezolizumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

24 of 35 total trials

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting
Relapsed/Refractory Small Cell Lung Cancer
Drug: Tarlatamab

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting
Multiple Sclerosis
Drug: Ocrelizumab

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling
Non-Small Cell Lung Cancer (NSCLC)
Drug: Sotorasib
Drug: Pembrolizumab

A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This stu...

Active, not recruiting
Paroxysmal Nocturnal Hemoglobinuria
Drug: Eculizumab
Drug: Crovalimab

The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A i...

Active, not recruiting
Hemophilia A
Drug: BAX 888

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this...

Active, not recruiting
ALK+ Advanced NSCLC
Drug: Brigatinib
Drug: Alectinib

The Phase 1b part of this study is conducted to assess the safety and tolerability of E7386 in combination with pembrolizumab in participants with pr...

Active, not recruiting
Melanoma
Carcinoma, Hepatocellular
Drug: E7386
Drug: Lenvatinib

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Amrubicin

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non...

Active, not recruiting
Carcinoma, Non-Small-Cell Lung
Drug: Ipatasertib
Drug: XL092

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, imp...

Active, not recruiting
Neoplasms by Site
Neoplasms, Nerve Tissue
Drug: Cisplatin
Drug: Pembrolizumab

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participa...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Tiragolumab
Drug: Atezolizumab

The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time thi...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Active, not recruiting
Gastric Cancer
Gastroesophageal Junction Adenocarcinoma
Drug: Bemarituzumab
Drug: mFOLFOX6

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling
Melanoma
Drug: Cemiplimab
Drug: Placebo

The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with SSc-ILD.

Enrolling
Diffuse Cutaneous Systemic Sclerosis
Interstitial Lung Disease
Diagnostic Test: Companion diagnostic ( CDx)
Drug: Placebo

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Enrolling
Non-Squamous Non-small Cell Lung Cancer
Drug: Placebo Injection
Drug: AK112 Injection

Researchers are looking for new ways to treat Limited-Stage Small Cell Lung Cancer (LS-SCLC), a type of lung cancer that has not spread from the lung...

Enrolling
Small Cell Lung Cancer
Drug: Platinum, investigator's choice
Biological: Pembrolizumab 400 mg

This trial is intended to study the safety and effectiveness of an new anti-epileptic drug (AED) on Primary Generalized Tonic-Clonic (PGTC) Seizures....

Enrolling
Primary Generalized Epilepsy
Drug: Placebo
Drug: Cenobamate

The main objective is to compare the efficacy of tarlatamab with standard of care (SOC) on prolonging overall survival (OS).

Enrolling
Small Cell Lung Cancer (SCLC)
Drug: Topotecan
Drug: Amrubicin

Trial sponsors

Amgen logo
Roche logo
Gilead Sciences logo
AbbVie logo
Pfizer logo
Biogen logo
Takeda logo
Baxalta logo
Daiichi Sankyo logo
D

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems